Enhanced effects of PPARγ ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells

Oncology Reports

Volumn 21, Issue 4, 2009, Pages 1083-1089

  Papi, A ^a   Rochhi, Paola ^a   Ferreri, A M ^a   Guerra, F ^a   Orlandi, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Ciglitazone; Invasion; Metalloproteinases; Nuclear receptors; Rexinoids

Indexed keywords

6 HYDROXY 11 O HYDROXYPHENANTRENE; CIGLITAZONE; GELATINASE A; GELATINASE B; LIGAND; MATRIX METALLOPROTEINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID; RETINOID X RECEPTOR; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; IIF COMPOUND; RETINOIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL GROWTH; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; CELL MOTION; DRUG EFFECT; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; DRUG SYNERGISM; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASMS; PPAR GAMMA; RETINOID X RECEPTORS; THIAZOLIDINEDIONES; TRETINOIN;

EID: 67449095059     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000327     Document Type: Article

References (37)

1. Grommes C, Landreth GE and Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 6: 419-429, 2004.
2. Michalik L, Auwerx J, Berger JP, et al: International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 58: 726-741, 2006.
3. Guan YF, Zhang YH, Breyer RM, Davis L and Breyer MD: Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1: 330-339, 1999.
4. Roman J: Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy. J Investig Med 56: 528-533, 2008.
5. Cerbon A, Toaldo C, Laurora S, Briatore F, Pizzimenti S, Dianzani MU, Ferretti C and Barrera G: 4-Hydroxynonenal and PPARgamma ligands affect proliferation, differentiation, and apoptosis in colon cancer cells. Free Radic Biol Med 42: 1661-1670, 2007.
6. Yoshizumi T, Ohta T, Ninomiya I, Terada I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S and Miwa K: Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int J Oncol 25: 631-639, 2004.
7. Krishnan A, Nair SA and Pillai MR: Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med 6: 532-540, 2007.
8. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y and Kinoshita Y: Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 4: 465-477, 2004.
9. Zoete V, Grosdidier A and Michielin O: Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 1771: 915-925, 2007.
10. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR and Gronemeyer H: RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6: 793-810, 2007.
11. Desjardins A, Rich JN, Quinn JA, et al: The retinoic acid paradox in cancer chemoprevention. J Natl Cancer Inst 98: 426-427, 2006.
12. Garattini E, Gianni M and Terao M: Retinoids as differentiating agents in oncology: a network of interactions with intracellular pathways as the basis for rational therapeutic combinations. Curr Pharm Des 13: 375-400, 2007.
13. Zhu J, Riaucoux-Lormière F, Honoré N, et al: RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 12: 23-35, 2007.
14. Kagechica H and Shudo K: Synthetic retinoids: recent development concerning structure and clinical utility. J Med Chem 48: 5875-5883, 2005.
15. Nahoum V, Pérez E, Germain P, et al: Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function. Proc Natl Acad Sci USA 104: 17323-17328, 2007.
16. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, De Lera AR, Lotan R, Mangelsdorf DJ and Gronemeyer H: International Union of Pharmacology. LXIII. Retinoid X receptors Pharmacol Rev 58: 760-772, 2006.
17. Kong G and Brown PH: The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxigenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. Cancer Res 65: 3462-3469, 2005.
18. Orlandi M, Mantovani B, Ammar K, Dal Monte P and Bartolini G: Retinoids and cancer: antitumoral effects of ATRA, 9-cisRA and the new retinoid IIF on the HL-60 leukemic cell line. Med Princ Pract 12: 164-169, 2003.
19. Papi A, Bartolini G, Ammar K, Guerra F, Ferreri AM, Rocchi P and Orlandi M: Inhibitory effects of retinoic acid and IIF on growth, migration and invasiveness in the U87MG human glioblastoma cell line. Oncol Rep 18: 1015-1021, 2007.
20. Bartolini G, Orlandi M, Ammar K, Magrini E, Ferreri AM and Rocchi P: Effect of a new derivative of retinoic acid on proliferation and differentiation in human neuroblastoma cells. Anticancer Res 23: 1495-1500, 2003.
21. Bartolini G, Ammar K, Mantovani B, Scannabissi F, Ferreri AM, Rocchi P and Orlandi M: Retinoid and cancer: antitumor effect of ATRA and of a new derivative of retinoic acid, IIF, on colon carcinoma cell lines CaCo-2 and HT-29. Anticancer Res 24: 1779-1783, 2004.
22. Bartolini G, Orlandi M, Papi A, Ammar A, Guerra A, Ferreri AM and Rocchi P: Search for multidrug resistance modulators: effects of retinoids in human colon carcinoma cells. In Vivo 20: 729-733, 2006.
23. Bartolini G, Orlandi M, Papi A, Ammar K, Tonelli R, Franzoni M, Pession A, Rocchi P and Ferreri AM: Growth inhibition and proapoptotic activity induction by IIF and Valproic acid on RA-resistant leukemia cells. Anticancer Res 28: 283-288, 2008.
24. Yaacob NS, Darus HM and Norazmi MN: Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone. Exp Toxicol Pathol (In press)
25. Yang YC, Tsao YP, Ho TC and Choung IP: Peroxisome proliferator-activated receptor-gamma agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines. Int J Gynecol Cancer 17: 418-425, 2006.
26. Shimizu M and Moriwaki H: Synergistic effects of PPAR ligands and retinoids in cancer treatment. PPAR Res 11555: 1-10, 2008.
27. Lee YR, Yu HN, Noh EM, Kim JS, Song EK, Han MK, Kim BS, Lee SH and Park J: Peroxisome proliferator-activated receptor gamma and retinoic acid receptor synergistically up-regulate the tumor suppressor PTEN in human promyeloid leukemia cells. Int J Hematol 85: 231-237, 2007.
28. Cesario RM, Stone J, Yen WC, Bissonnette RP and Lamph WW: Differentiation and growth inhibition mediated via the RXR: PPARgamma heterodimer in colon cancer. Cancer Lett 240: 225-233, 2005.
29. Yamazaki K, Shimizu M, Okuno M, et al: Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells phosphorylated RXR alpha is a critical target for colon cancer management. Gut 56: 1557-1563, 2007.
30. Hellemans K, Kerckhofs K, Hannaert JC, Martens G, Van Veldhoven P and Pipeleers D: Peroxisome proliferator-activated receptor alpha-retinoid X receptor agonists induce beta-cell protection against palmitate toxicity. FEBS J 274: 6094-6105, 2007.
31. Ziouzenkova O and Plutzky J: Retinoid metabolism and nuclear receptor responses: New insights into coordinated regulation of the PPAR-RXR complex. FEBS Lett 582: 32-38, 2008.
32. Crowe DL and Chandraratna RA: A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 6: 546-555, 2004.
33. Clark IM, Swingler TE, Sampieri CL and Edwards DR: The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40: 1362-1378, 2008.
34. López-Otín C and Matrisian LM: Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7: 800-808, 2007.
35. Rydlova M, Holubec L, Ludvikova M, Kalfert D, Franekova J, Povysil C and Ludvikova M: Biological activity and clinical implications of the matrix metalloproteinases. Anticancer Res 28: 1389-1397, 2008.
36. Park EY, Cho I and Sang GK: Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione Stransferase gene by the peroxisome proliferator-activated receptor-γ and retinoid X Receptor heterodimer. Cancer Res 64: 3701-3713, 2007.
37. Lazar MA: PPAR gamma, 10 years later. Biochimie 87: 9-13, 2005.